High-dose-rate brachytherapy in combination with conformal external beam radiotherapy in the treatment of prostate cancer

Brachytherapy

Volumn 9, Issue 1, 2010, Pages 27-35

  Zwahlen, Daniel R ^a,b   Andrianopoulos, Nick ^b   Matheson, Bronwyn ^a,b   Duchesne, Gillian M ^c,d   Millar, Jeremy L ^a,b  

^a ALFRED HOSPITAL   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c PETER MACCALLUM CANCER CENTRE   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Brachytherapy; Dose escalation; High dose rate; Prostate cancer; Radiotherapy

Indexed keywords

ANTIANDROGEN;

ADJUVANT THERAPY; ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ARGON PLASMA COAGULATION; ARTICLE; BRACHYTHERAPY; CANCER ADJUVANT THERAPY; CANCER CONTROL; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; COMPUTER ASSISTED RADIOTHERAPY; CONTROLLED STUDY; DIARRHEA; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; GLEASON SCORE; HEMATURIA; HIGH RISK PATIENT; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MORBIDITY; NOCTURIA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE; RADIATION DOSE FRACTIONATION; RECTUM DISEASE; RECTUM HEMORRHAGE; TRANSURETHRAL RESECTION; TREATMENT OUTCOME; URETHRA STRICTURE; URETHROTOMY; URINARY FREQUENCY;

AGED; AUSTRALIA; BRACHYTHERAPY; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; HUMANS; MALE; MIDDLE AGED; PREVALENCE; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE; RADIOTHERAPY, CONFORMAL; SURVIVAL ANALYSIS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 72449132293     PISSN: 15384721     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brachy.2009.04.007     Document Type: Article

References (36)

1. Dearnaley D.P., Sydes M.R., Graham J.D., et al. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: First results from the MRC RT01 randomised controlled trial. Lancet Oncol 8 (2007) 475-487
2. Zelefsky M.J., Chan H., Hunt M., et al. Long-term outcome of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer. J Urol 176 (2006) 1415-1419
3. Sathya J.R., Davis I.R., Julian J.A., et al. Randomized trial comparing iridium implant plus external-beam radiation therapy with external-beam radiation therapy alone in node-negative locally advanced cancer of the prostate. J Clin Oncol 23 (2005) 1192-1199
4. Hoskin P.J., Motohashi K., Bownes P., et al. High dose rate brachytherapy in combination with external beam radiotherapy in the radical treatment of prostate cancer: Initial results of a randomised phase three trial. Radiother Oncol 84 (2007) 114-120
5. Duchesne G.M., Williams S.G., Das R., et al. Patterns of toxicity following high-dose-rate brachytherapy boost for prostate cancer: Mature prospective phase I/II study results. Radiother Oncol 84 (2007) 128-134
6. Kalkner K.M., Wahlgren T., Ryberg M., et al. Clinical outcome in patients with prostate cancer treated with external beam radiotherapy and high dose-rate iridium 192 brachytherapy boost: a 6-year follow-up. Acta Oncol 46 (2007) 909-917
7. Phan T.P., Syed A.M., Puthawala A., et al. High dose rate brachytherapy as a boost for the treatment of localized prostate cancer. J Urol 177 (2007) 123-127 discussion 127
8. Galalae R.M., Martinez A., Mate T., et al. Long-term outcome by risk factors using conformal high-dose-rate brachytherapy (HDR-BT) boost with or without neoadjuvant androgen suppression for localized prostate cancer. Int J Radiat Oncol Biol Phys 58 (2004) 1048-1055
9. ASTRO Consensus Panel. Consensus statement: guidelines for PSA following radiation therapy. American Society for Therapeutic Radiology and Oncology Consensus Panel. Int J Radiat Oncol Biol Phys 37 (1997) 1035-1041
10. Roach III M., Hanks G., Thames Jr. H., et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 65 (2006) 965-974
11. Hsu I.C., Pickett B., Shinohara K., et al. Normal tissue dosimetric comparison between HDR prostate implant boost and conformal external beam radiotherapy boost: Potential for dose escalation. Int J Radiat Oncol Biol Phys 46 (2000) 851-858
12. Pieters B.R., van de Kamer J.B., van Herten Y.R., et al. Comparison of biologically equivalent dose-volume parameters for the treatment of prostate cancer with concomitant boost IMRT versus IMRT combined with brachytherapy. Radiother Oncol 88 (2008) 46-52
13. Morton G.C. The emerging role of high-dose-rate brachytherapy for prostate cancer. Clin Oncol (R Coll Radiol) 17 (2005) 219-227
14. Duchesne G.M., and Peters L.J. What is the alpha/beta ratio for prostate cancer? Rationale for hypofractionated high-dose-rate brachytherapy. Int J Radiat Oncol Biol Phys 44 (1999) 747-748
15. Williams S.G., Taylor J.M., Liu N., et al. Use of individual fraction size data from 3756 patients to directly determine the alpha/beta ratio of prostate cancer. Int J Radiat Oncol Biol Phys 68 (2007) 24-33
16. UICC. TNM classification of malignant tumours. 6th ed. (2002), John Wiley & Sons, New York, NY
17. NCCN Clinical practice guidelines in oncology. Prostate cancer. V.2.2009; 2009. Available at: http://www.nccn.org/professionals/physician_gls/PDF/prostate.pdf. Accessed August 31, 2009.
18. Cox J.D., Stetz J., and Pajak T.F. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 31 (1995) 1341-1346
19. Pavy J.J., Denekamp J., Letschert J., et al., EORTC Late Effects Working Group. Late effects toxicity scoring: The SOMA scale. Int J Radiat Oncol Biol Phys 31 (1995) 1043-1047
20. Sato M., Mori T., Shirai S., et al. High-dose-rate brachytherapy of a single implant with two fractions combined with external beam radiotherapy for hormone-naive prostate cancer. Int J Radiat Oncol Biol Phys 72 (2008) 1002-1009
21. Jereczek-Fossa B.A., and Orecchia R. Evidence-based radiation oncology: Definitive, adjuvant and salvage radiotherapy for non-metastatic prostate cancer. Radiother Oncol 84 (2007) 197-215
22. Kumar S., Shelley M., Harrison C., et al. Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer. Cochrane Database Syst Rev 4 (2006) CD006019
23. Martinez A., Galalae R., Gonzalez J., et al. No apparent benefit at 5 years from a course of neoadjuvant/concurrent androgen deprivation for patients with prostate cancer treated with a high total radiation dose. J Urol 170 (2003) 2296-2301
24. Vargas C., Martinez A., Galalae R., et al. High-dose radiation employing external beam radiotherapy and high-dose rate brachytherapy with and without neoadjuvant androgen deprivation for prostate cancer patients with intermediate- and high-risk features. Prostate Cancer Prostatic Dis 9 (2006) 245-253
25. Williams S.G., Pickles T., Kestin L.L., et al. Androgen deprivation therapy plus hypofractionated prostate radiotherapy-Are we castrating the radiobiological advantage?. Int J Radiat Oncol Biol Phys 72 Suppl. 1 (2008) 73 [abstract]
26. Widmark A., Klepp O., Solberg A., et al. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): An open randomised phase III trial. Lancet 91 (2008) 232-236
27. Zapatero A., Valcarcel F., Calvo F.A., et al. Risk-adapted androgen deprivation and escalated three-dimensional conformal radiotherapy for prostate cancer: Does radiation dose influence outcome of patients treated with adjuvant androgen deprivation? A GICOR study. J Clin Oncol 23 (2005) 6561-6568
28. Vicini F.A., Vargas C., Edmundson G., et al. The role of high-dose rate brachytherapy in locally advanced prostate cancer. Semin Radiat Oncol 13 (2003) 98-108
29. Demanes D.J., Rodriguez R.R., Schour L., et al. High-dose-rate intensity-modulated brachytherapy with external beam radiotherapy for prostate cancer: California endocurietherapy's 10-year results. Int J Radiat Oncol Biol Phys 61 (2005) 1306-1316
30. Bentzen S.M., Dorr W., Anscher M.S., et al. Normal tissue effects: Reporting and analysis. Semin Radiat Oncol 13 (2003) 189-202
31. Sullivan L., Williams S.G., Tai K.H., et al. Urethral stricture following high dose rate brachytherapy for prostate cancer. Radiother Oncol (2008)
32. Michalski J.M., Winter K., Purdy J.A., et al. Toxicity after three-dimensional radiotherapy for prostate cancer on RTOG 9406 dose Level V. Int J Radiat Oncol Biol Phys 62 (2005) 706-713
33. Cahlon O., Zelefsky M.J., Shippy A., et al. Ultra-high dose (86.4 Gy) IMRT for localized prostate cancer: Toxicity and biochemical outcomes. Int J Radiat Oncol Biol Phys 71 (2008) 330-337
34. Zietman A.L., DeSilvio M.L., Slater J.D., et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: A randomized controlled trial. JAMA 294 (2005) 1233-1239
35. Nguyen P.L., and Zietman A.L. High-dose external beam radiation for localized prostate cancer: Current status and future challenges. Cancer J 13 (2007) 295-301
36. Ritter M. Rationale, conduct, and outcome using hypofractionated radiotherapy in prostate cancer. Semin Radiat Oncol 18 (2008) 249-256